Lux Biosciences GmbH withdraws marketing authorisation application for voclosporin (Luveniq)

Source: European Medicines Agency (EMA)
Area: News
The European Medicines Agency (EMA) has announced that it has been formally notified by Lux Biosciences GmbH of its decision to withdraw its application for a centralised marketing authorisation for the medicine voclosporin 10 mg soft capsules (Luveniq). Voclosporin was intended to be used for the treatment of patients with chronic non-infectious uveitis involving the posterior or intermediate segments of the eyes as characterised by a high degree of inflammation and in whom corticosteroids are inappropriate, do not provide adequate control, or cannot (Read more...)

Full Story →